2.57
-0.01(-0.39%)
Currency In USD
| Previous Close | 2.58 |
| Open | 2.51 |
| Day High | 2.62 |
| Day Low | 2.46 |
| 52-Week High | 7.25 |
| 52-Week Low | 1.85 |
| Volume | 576,345 |
| Average Volume | 1.95M |
| Market Cap | 259.33M |
| PE | -1.03 |
| EPS | -2.5 |
| Moving Average 50 Days | 2.5 |
| Moving Average 200 Days | 3.9 |
| Change | -0.01 |
If you invested $1000 in Acelyrin, Inc. (SLRN) since IPO date, it would be worth $142.78 as of May 04, 2025 at a share price of $2.57. Whereas If you bought $1000 worth of Acelyrin, Inc. (SLRN) shares 1 year ago, it would be worth $588.1 as of May 04, 2025 at a share price of $2.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
GlobeNewswire Inc.
May 01, 2025 5:30 PM GMT
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biop
Alumis and ACELYRIN Announce Amended Merger Agreement
GlobeNewswire Inc.
Apr 21, 2025 10:30 AM GMT
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
GlobeNewswire Inc.
Mar 13, 2025 11:00 AM GMT
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response